Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01894217 · ClinicalTrials.gov registry record · Phase 1

Statin Therapy to Improve Medication Adherence

A Phase 1 study, sponsored by Duke University.

Completed
Registry status
Phase 1
Development phase
63
Enrollment target

NCT01894217 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 63 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01894217, a Phase 1 study, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 1
Development phase
63 participants
Enrollment target

Study Summary

The purpose of this pilot study is to examine if using genetics can improve statin adherence in patients who should be taking statins but are not because of prior side effects with statins. This study will assist physicians in making a personalized health care plan for prevention of cardiovascular disease.

Interventions

  • GENETIC Genetic testing and reporting for SLCO1B1*5 allele

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2011-05
Est. Completion 2014-04
Phase Phase 1

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT01894217

The ClinicalTrials.gov registry entry for NCT01894217 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Genetic testing and reporting for SLCO1B1*5 allele is the first listed.

NCT01894217 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01894217 about?

NCT01894217 is a clinical study titled "Statin Therapy to Improve Medication Adherence". The purpose of this pilot study is to examine if using genetics can improve statin adherence in patients who should be taking statins but are not because of prior side effects with statins. This study will assist physicians in making a personalized health care plan for prevention of cardiovascular d...

What is the current status of trial NCT01894217?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2011-05. Estimated completion is 2014-04.

What interventions are being tested in trial NCT01894217?

The interventions under investigation include: Genetic testing and reporting for SLCO1B1*5 allele (GENETIC).

Who is sponsoring clinical trial NCT01894217?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.